林璐;吴伟英;刘晓琦;曾英彤;劳海燕;杨敏;
LIN Lu;WU Weiying;LIU Xiaoqi;ZENG Yingtong;LAO Haiyan;YANG Min;Department of Pharmacy,Guangdong General Hospital ( Guangdong Academy of Medical Sciences );Guangdong Pharmaceutical University;Guangdong Provincial Cardiovascular Research Institute;

• 1:广东省人民医院(广东省医学科学院)药学部
• 2:广东药科大学
• 3:广东省心血管病研究所

摘要(Abstract)：

目的系统评价盐酸氨溴索注射剂雾化吸入与静脉注射的有效性和安全性。方法采用Cochrane系统评价方法,检索中英文电子数据库,由两名评价者独立评价并交叉核对纳入研究的质量,把最终纳入的研究采用Rev Man5.2软件进行Meta分析。结果 Meta分析共纳入25个随机对照试验,包括2 392例患者,其中吸入组1 195例,静注组1 197例。有效性方面,在PPCs预防组、成人呼吸系统感染组和老年COPD组,吸入组的临床总有效率均大于静注组,差异有统计学意义[OR=2.33,95%CI=(1.23,4.42),P=0.009; OR=3.06,95%CI=(1.71,5.46),P=0.000 2; OR=4.98,95%CI=(1.98,12.45),P=0.000 7];而在儿童肺炎组,两组的差异无统计学意义[OR=1.44,95%CI=(0.88,2.37),P=0.14];在早产儿NRDS预防组,静注组的NRDS发生率小于吸入组,差异有统计学意义[OR=2.38,95%CI=(1.13,5.02),P=0.02]。安全性方面,吸入组的不良反应发生率小于静注组,差异有统计学意义[OR=0.33,95%CI=(0.15,0.72),P=0.000 5]。结论雾化吸入氨溴索注射剂在预防PPCs和治疗成人肺部疾病是安全有效的,甚至优于静脉注射给药,但在儿童患者的使用上有待商榷。尚需设计良好的随机对照试验加以评价,并确定雾化吸入的合理剂量和疗程。
OBJECTIVE To systematically review the efficacy and safety of ambroxol injection by inhalation versus intravenous administration. METHODS Followed the Cochrane Collaboration methodology and searched relevant electronic databases. The quality of the included studies was evaluated independently by two reviewers,RevMan5.2 was used to perform the meta-analysis. RESULTS A total of 2 392 patients from 25 RCTs were included,of which the inhalation group contained 1 195 cases,injection group 1 197 cases.The total effective rate of inhalation was higher than intravenous injection of ambroxol hydrochloride in the PPCs prevention group,adult respiratory infections group and elder COPD group,with significant difference [OR = 2. 33,95% CI =( 1. 23,4. 42),P = 0. 009; OR =3.06,95%CI =(1.71,5. 46),P = 0. 000 2; OR = 4. 98,95% CI =( 1. 98,12. 45),P = 0. 000 7]. However,no significant difference was observed in the subgroup of childhood pneumonia [OR = 1.44,95%CI =(0.88,2.37),P = 0.14]. But in the NRDS prevention group,the incidence of NRDS of intravenous injection was lower than inhalation of ambroxol hydrochloride,with significant difference [OR = 2.38,95%CI =(1.13,5.02),P = 0.02]. The incidence of adverse reactions in the inhalation group was less than that of intravenous injection group,with significant difference [OR = 0. 33,95% CI =( 0. 15,0. 72),P = 0. 000 5]. CONCLUSION Compared with intravenous administration,inhalation of ambroxol hydrochloride is safe and effective in the prevention of PPCs and treatment of adult lung disease,but still remains questionable for children patients. More well-designed randomized controlled trials are needed to confirm the results,and to establish a reasonable dose and course for inhalation of ambroxol injection.

关键词(KeyWords)： 氨溴索;雾化吸入;静脉注射;系统评价
ambroxol;inhalation;injection;systematic review

Abstract:

Keywords:

基金项目(Foundation): 广州市科技计划项目(201509010012)

作者(Author): 林璐;吴伟英;刘晓琦;曾英彤;劳海燕;杨敏;
LIN Lu;WU Weiying;LIU Xiaoqi;ZENG Yingtong;LAO Haiyan;YANG Min;Department of Pharmacy,Guangdong General Hospital ( Guangdong Academy of Medical Sciences );Guangdong Pharmaceutical University;Guangdong Provincial Cardiovascular Research Institute;

Email:

DOI:

参考文献(References)：

• [1]雷光萍,陈汝婷.盐酸氨溴索不同给药途径对慢性阻塞性肺疾病急性加重期疗效的影响[J].临床合理用药杂志,2016,9(24):40-41.
• [2]Zhang S J,Jiang J X,Ren Q Q,et al. Ambroxol inhalation ameliorates LPS-induced airway inflammation and mucus secretion through the extracellular signal-regulated kinase 1/2 signaling pathway[J].Eur J Pharmacol,2016,775(1):138-148.
• [3]万思慧,张文静,陈礼治,等.氨溴索防治术后肺部并发症的疗效及安全性的直接和间接比较[J].世界临床药物,2015,36(3):161-168.
• [4] Ren Y C,Wang L,He H B,et al. Pulmonary selectivity and local pharmacokinetics of ambroxol hydrochloride dry powder inhalation in rat[J]. Journal of Pharmaceutical Sciences,2009,98(5):1797-1803.
• [5]Heijerman H,Westerman E,Conway S,et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis:A European consensus[J]. J Cyst Fibros,2009,8(5):295-315.
• [6]Sablotzki A,Starzmann W,Scheubel R,et al. Selective pulmonary vasodilation with inhaled aerosolized milrinone in heart transplant candidates[J]. Can J Anaesth,2005,52(10):1076-1082.
• [7]杨敏,麻安秀.沐舒坦两种给药途径对腹部手术后排痰困难的效果观察[J].临床护理杂志,2008,7(6):31-32.
• [8]杨芳.沐舒坦不同给药途径对于肺癌手术患者的护理疗效观察[J].临床医学研究与实践,2016,1(13):168.
• [9]田凯华,李高升,沈毅,等.氨溴索防治肺部手术并发症的疗效观察[J].山东医药,2010,50(12):63-64.
• [10]陶义鹏,王婉玲,赵宝生.氨溴索防治高龄食管癌手术后肺部并发症的疗效[J].现代肿瘤医学,2011,19(8):1586-1587.
• [11]李俊,余荣环,黄运平,等.沐舒坦不同给药途径治疗AECOPD的疗效观察[J].临床肺科杂志,2007,12(11):1169-1170.
• [12]于红.氨溴索不同给药途径治疗老年慢性阻塞性肺病疗效观察[J].临床肺科杂志,2008,13(2):212-213.
• [13]项燕鸥.氨溴索雾化吸入治疗慢性阻塞性肺疾病急性加重期疗效观察[J].海峡药学,2011,23(2):79-81.
• [14]王海军,林芳.盐酸氨溴索不同给药途径治疗慢性阻塞性肺疾病疗效[J].医学信息,2014,27(5):557.
• [15]邬春雷.氨溴索不同给药途径治疗支气管肺炎疗效[J].医学信息(中旬刊),2011,24(4):1428.
• [16]许云,杨泽民,王济国.氨溴索雾化吸入治疗社区获得性肺炎的效果评价[J].深圳中西医结合杂志,2015,25(23):82-84.
• [17]王宋和,程嬿.沐舒坦注射液治疗慢性支气管炎240例疗效观察[J].中国民族民间医药,2009,18(10):117-118.
• [18]曾涛.沐舒坦雾化吸入治疗老年慢性支气管炎急性发作临床观察[J].北方药学,2015,12(12):47-48.
• [19]鲍国玉,马立刚,刘天成,等.氨溴索不同用药途径治疗呼吸系统疾病疗效观察[J].中国医疗前沿,2009,4(20):34-35.
• [20]占剑青,张卫清.氨溴索氧气驱动雾化吸入与静脉用药辅助治疗呼吸道感染的疗效对比[J].中医临床研究,2009,1(2):68,70.
• [21]仲玉兰.盐酸氨溴索雾化吸入与静脉滴注的临床效果对比[J].中西医结合心血管病电子杂志,2014,2(7):99-100.
• [22]胡琴,连金媚,李俭庆.沐舒坦不同给药方式预防早产儿呼吸窘迫综合征疗效观察[J].中国当代儿科杂志,2006,8(4):301-303.
• [23]何玲,张秀凤,符宗敏,等.盐酸氨溴索不同给药方式对预防新生儿早产肺透明膜病观察[J].昆明医学院学报,2009,30(7):64-66.
• [24]陈敏,黎晓兰,金德华.盐酸氨溴索不同给药方式对早产儿肺透明膜病的预防效果研究[J].现代医学,2016,44(5):640-643.
• [25]蔡仪术,陈国春,梁文宝.不同给药途径氨溴索治疗新生儿胎粪吸入性肺炎疗效观察[J].现代中西医结合杂志,2014,23(11):1205-1206.
• [26]包捷报.盐酸氨溴索不同给药方式辅助治疗小儿肺炎的临床效果观察[J].临床合理用药杂志,2014,7(7B):29-30.
• [27]赵立明,刘海燕.氨溴索不同给药方式治疗新生儿肺炎临床疗效分析[J].临床肺科杂志,2013,18(6):1135-1136.
• [28]黄昌洪,付宏.氨溴索不同给药途径治疗新生儿胎粪吸入性肺炎的疗效观察[J].中国医药导报,2011,8(31):85-86.
• [29]赵娟.氨溴索在治疗小儿毛细支气管炎中的疗效观察[J].中国现代药物应用,2011,5(1):90.
• [30]董静,李亚娟,张连英.氨溴索不同途径给药治疗婴幼儿肺炎疗效比较[J].实用诊断与治疗杂志,2007,21(10):776-777.
• [31]杨伟钦,许德超,白丽燕.氨溴索不同给药途径佐治婴幼儿肺炎的疗效比较[J].儿科药学杂志,2005,11(1):31-32.
• [32]解农祥.盐酸氨溴索不同给药方式治疗儿科呼吸系统疾病的效果比较[J].实用心脑肺血管病杂志,2014,22(11):71-72.
• [33]Yong B,Chen J,Zhu R,et al. Upregulation of AQP3 and AQP5 induced by dexamethasone and ambroxol in A549 cells[J]. Respiratory Physiology& Neurobiology,2008,161(2):111.
• [34]张琼.盐酸氨溴索的药理和临床分析[J].中国实用医药,2009,4(35):111-112.
• [35]Li F,Yu J,Yang H,et al. Effects of ambroxol on alginate of mature Pseudomonas aeruginosa biofilms[J]. Current Microbiology,2008,57(1):1.
• [36]Lu Q,Yu J L,Yang X Q,et al. Ambroxol interferes with Pseudomonas aeruginosa quorum sensing[J]. International Journal of Antimicrobial Agents,2010,36(3):211.
• [37] Wauer R R,Schmalisch G,Hme B B,et al. Randomized double blind trial of Ambroxol for the treatment of respiratory distress syndrome[J]. European Journal of Pediatrics,1992,151(5):357-363.
• [38]Chander S. Cell-specific modulation of surfactant proteins by ambroxol treatment[J]. Toxicology& Applied Pharmacology,2005,203(1):27.
• [39]董硕.不同剂量盐酸氨溴索对开胸手术围术期肺保护作用的研究[D].长沙:中南大学,2012.
• [40]李立荣.氨溴索不同剂量雾化吸入治疗慢性支气管炎的临床疗效分析[J].医学信息(下旬刊),2013,26(12):702.
• [41]刘建芳.氨溴索不同剂量雾化吸入治疗慢性支气管炎临床疗效分析[J].中外医学研究,2011,9(23):40-41.
• [42]王明丽,谢陶吟,许建平.注射用氨溴索雾化吸入致呼吸困难1例分析[J].中国药房,2011,22(40):3791-3792.
• [43]黄元,李泮海,田月洁. 40例盐酸氨溴索注射剂致严重不良反应/事件分析[J].中国药物警戒,2013,10(3):163-165.
• [44]刘胜龙.注射用盐酸氨溴索祛痰作用的临床疗效与不良反应[J].中国医药指南,2013,11(14):131.
• [45]李玲,高雁,葛泉丽,等.盐酸氨溴索注射液不良反应研究综述[J].广州化工,2015,43(14):33-34.
• [46]Schulz K F,Chalmers I,Hayes R J,et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials[J]. JAMA,1995,273(5):408-412.